Healthcare’s most effective leaders are often those willing to leave the safety of traditional paths and brave the discomfort of reinvention. In a compelling episode of Leadership Rounds, Oxeon’s Dr. Reena Pande speaks with Andrew Norden, MD, a neuro-oncologist-turned-healthcare executive whose career spans academic medicine, big tech, startups, and payer-facing oncology innovation.
Andrew’s story is not a neat ascent. It is a candid, instructive account of curiosity, missteps, ethical clarity, and the growing need for clinician leadership across healthcare’s most complex systems.
Andrew’s early career followed a traditional (and highly successful) academic trajectory. Trained in neurology and neuro-oncology at Dana-Farber Cancer Institute, he loved patient care and found deep meaning in oncology relationships. But early on, a tension emerged in that the impact of seeing one patient at a time felt insufficient. Like many clinician leaders, Andrew began to ask how he could help more patients than he could ever see himself in a one-on-one setting.
That question pushed him toward systems-level thinking. His first pivot came from within academia, serving as medical director of Dana-Farber’s growing community oncology network, where he helped build programs that brought high-quality cancer care closer to patients’ homes.
It was here that Andrew discovered a truth many clinicians encounter: healthcare systems, not individual effort, determine scale.
Andrew’s transition was shaped by two contrasting mentor experiences that were both deeply instructive.
One mentor, Dana-Farber’s chief medical officer, invited Andrew into operational leadership and actively sponsored his growth. Another mentor, however, responded to Andrew’s interest in non-traditional work with words Andrew would never forget: “You’re throwing your career in the toilet.”
That second experience was painful, but clarifying. Andrew emphasizes that leaving academia can feel like a breakup: emotionally charged, identity-shaking, and deeply personal. Yet, over time, even fractured relationships can heal when both sides recognize that impact takes many forms. In the end, he learned that the right mentors care about your contribution to the world, not just your CV.
Without clear visibility into non-academic roles, Andrew did something deceptively simple. He asked questions. Lots of them. He walked into offices. He asked for advice (not jobs). He invested in a physician career coach to understand options across pharma, payers, consulting, startups, and technology. And he built a web of relationships driven by learning, not transactions. This approach ultimately led him to his first major leap outside academia at IBM Watson Health.
IBM Watson Health promised world-changing AI for oncology in systems that could read medical records and recommend treatment. The vision was intoxicating. The reality was sobering.
Once inside, Andrew realized the products were not ready, and in some cases, potentially unsafe. Worse, his role was positioned largely to lend clinical credibility to sales, not to meaningfully shape product integrity. Within nine months, Andrew made a difficult but values-driven decision to leave.
Looking back, he never saw a real product demo, which he identifies as a critical mistake. That lesson is now central to his advice for clinician executives: if you are asked to stand behind a product, you must be allowed to understand it (under NDA if necessary). This experience sharpened Andrew’s skepticism and reinforced the clinician’s responsibility to protect patient trust, even at personal cost.
Andrew’s next chapters looked very different. At COTA Healthcare and later as Chief Medical Officer at OncoHealth, he applied hard-earned lessons to make impact quickly and credibly.
His advice to clinicians entering startups is refreshingly practical:
Clinicians, Andrew notes, often underestimate how valuable their core skills already are.
In one of the episode’s most provocative moments, Andrew addresses his current role as the leader of clinical strategy at an oncology utilization management company, a space often viewed skeptically by clinicians. His stance is nuanced. Utilization management can play a constructive role when guided by strong clinical leadership, transparency, and a patient-first lens. With cancer therapies growing exponentially more complex and costly, clinicians need support, not just constraints. Andrew’s message is not that utilization management is perfect, but that it is too important to leave without clinicians in the room.
Healthcare is increasingly shaped by forces outside traditional medicine. Technology, capital, and policy are all playing increasingly important roles. Andrew’s trajectory illustrates why clinicians must not opt out of these arenas, and at Oxeon, we work with leaders navigating exactly these transitions: clinicians stepping into executive roles, companies seeking ethical, systems-minded leadership, and organizations balancing scale with trust.
Andrew’s story offers a clear takeaway we are hearing from leaders across the board. If clinicians don’t help build the future of healthcare, they may not like what emerges.
Listen on Spotify or Apple Podcasts
Andrew Norden, MD, MPH, MBA, is a neuro-oncologist and physician executive who serves as Chief Medical Officer of OncoHealth, a leading oncology management company dedicated to helping health plans, employers, oncologists, and patients navigate the physical, emotional, and financial complexities of cancer care. In this role, he leads clinical strategy, medical affairs, and innovation initiatives designed to improve oncology outcomes and care delivery.
Dr. Norden previously served as Chief Medical Officer of COTA and as Deputy Chief Health Officer and lead physician for oncology and genomics at IBM Watson Health. Earlier in his career, he practiced neuro-oncology and conducted research focused on improving outcomes for patients with brain tumors.
He is the author of more than 65 peer-reviewed publications and serves as an Associate Editor of JCO Clinical Cancer Informatics. Dr. Norden is an active member of the American Society of Clinical Oncology (ASCO) and the Society for Neuro-Oncology.
